BioCentury | Jan 16, 2012
Company News

Bioleap, Kyorin deal

...in vivo. Terms were not disclosed. Kyorin's R&D focuses on respiratory, urology and infectious areas. BioLeap Inc....
BioCentury | Dec 19, 2011
Company News

Bioleap, Southern Research Institute deal

...BioLeap and Southern Research partnered to use BioLeap's computational fragment-based design technology to discover therapeutics to...
...computational fragment-based design technology to discover therapeutics to treat undisclosed indications. Terms were not disclosed. BioLeap Inc....
BioCentury | Jul 14, 2011
Strategy

Rethinking mechanisms of drug discovery

...Fulmer, T. SciBX 4 (27); doi:10.1038/scibx.2011.755 Published online July 14, 2011 Companies and Institutions Mentioned BioLeap Inc....
...cancer," said Young. While e-Therapeutics uses computational techniques to tackle the biological complexity of targets, BioLeap Inc....
...clinical parameters" such as pharmacokinetics and pharmacodynamics. To help work out those subtle binding interactions, BioLeap...
BioCentury | Jan 18, 2010
Financial News

Bioleap completes venture financing

BioLeap Inc. , New Hope, Pa. Business: Computational chemistry/biology Date completed: 1/12/10 Type: Venture financing Raised: $5 million Investors: Adams Capital Management; Quaker BioVentures WIR Staff...
BioCentury | Sep 14, 2009
Company News

BioLeap LLC, GlaxoSmithKline deal

...design technology to develop compounds against undisclosed targets for GlaxoSmithKline. Further terms were not disclosed. BioLeap...
Items per page:
1 - 5 of 5
BioCentury | Jan 16, 2012
Company News

Bioleap, Kyorin deal

...in vivo. Terms were not disclosed. Kyorin's R&D focuses on respiratory, urology and infectious areas. BioLeap Inc....
BioCentury | Dec 19, 2011
Company News

Bioleap, Southern Research Institute deal

...BioLeap and Southern Research partnered to use BioLeap's computational fragment-based design technology to discover therapeutics to...
...computational fragment-based design technology to discover therapeutics to treat undisclosed indications. Terms were not disclosed. BioLeap Inc....
BioCentury | Jul 14, 2011
Strategy

Rethinking mechanisms of drug discovery

...Fulmer, T. SciBX 4 (27); doi:10.1038/scibx.2011.755 Published online July 14, 2011 Companies and Institutions Mentioned BioLeap Inc....
...cancer," said Young. While e-Therapeutics uses computational techniques to tackle the biological complexity of targets, BioLeap Inc....
...clinical parameters" such as pharmacokinetics and pharmacodynamics. To help work out those subtle binding interactions, BioLeap...
BioCentury | Jan 18, 2010
Financial News

Bioleap completes venture financing

BioLeap Inc. , New Hope, Pa. Business: Computational chemistry/biology Date completed: 1/12/10 Type: Venture financing Raised: $5 million Investors: Adams Capital Management; Quaker BioVentures WIR Staff...
BioCentury | Sep 14, 2009
Company News

BioLeap LLC, GlaxoSmithKline deal

...design technology to develop compounds against undisclosed targets for GlaxoSmithKline. Further terms were not disclosed. BioLeap...
Items per page:
1 - 5 of 5